Video

Dr. Park on Using CD19-Targeted CAR T Cells as Treatment for ALL

Author(s):

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.

Park says these patients have a very poor prognosis in overall survival, with previous studies showing an overall survival of less than 10%.

In order to improve the survival of these patients, researchers have modified patients’ own T cells to express CAR to target CD19, which is expressed in all patients with B-Cell ALL, Park says.

Using these modified CAR T cells, researchers have treated up to 33 patients. Of the 27 patients that were evaluable for response, 24 patients achieved complete response for a CR rate of 80%, Park says. Those patients that achieved a complete response, the majority of them were MRD-, which proves that the treatment is providing a deep response, despite that these are very high-risk patients.

<<<

View more from the 2014 ASH Annual Meeting

Related Videos
Shella Saint Fleur-Lominy, MD, PhD
Manali Kamdar, MD
Ibrahim Aldoss, MD
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
Sattva S. Neelapu, MD
Sattva S. Neelapu, MD
Julie M. Vose, MD, MBA
Lakshmi Nayak, MD
John Burke, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA